Alnylam - מכפיל EV/Sales ALNY

לוגו של חברה ציבורית alnylam.com (ALNY)

Alnylam Pharmaceuticals (ALNY) minimizes capital expenditures by outsourcing drug production to CMO partners. The commercialization of unique patents ensures inelastic demand and predictable revenue. The current EV/Sales level demonstrates the synergy of these factors, with the latest reading standing at 3831.50. A positive trend is supported by the expansion of the global RNA interference therapy market and an increasing patient population.

Alnylam Pharmaceuticals - יחס שווי פעילות להכנסות ALNY (תקופה 23.11.2025 - 20.11.2026)

Alnylam Pharmaceuticals, Inc. - פילוחים אנליטיים ומדדי מפתח (ALNY)

- מידע על כספים ותזרימי מזומנים:
ניתוח ראשוני של החברה:alnylam.com - ALNY
מוצר סדרתי של Alnylam

Fundamental issuer selection is based on comparing the market value of a business with its actual ability to generate cash flow. This indicator measures the total enterprise value, including debt, relative to annual sales volume, excluding the influence of capital structure. The possession of in-house RNA drug manufacturing capacities in the US stabilizes revenue, making the EV/Sales multiple of Alnylam Pharmaceuticals (ALNY) a reliable tool for assessing operational efficiency.